Status and phase
Conditions
Treatments
About
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period):
a. As determined by the site investigator, within 72 hours prior to vaccination.
i. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol. b. Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline, on Day 1 prior to vaccination. c. Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration.
Participant has had a positive COVID test within 90 days prior to screening.
Current or planned participation in any other interventional clinical trial.
Participation in research involving any investigational product within 45 days prior to study vaccination.
Receipt of any approved or authorized products intended to prevent SARS-CoV2 infection within 6 months prior to study vaccination.
Receipt or donation of blood products or immunoglobulins within 60 days prior to enrollment or planned administration during the study.
Received influenza vaccination within 14 days prior to study vaccination, or any other vaccine within 30 days prior to study vaccination.
Any autoimmune or immunodeficiency disease/condition (including and not limited to untreated or advanced HIV infection with CD4 counts <200 cells/mm^3, history of AIDS defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV, severe combined immunodeficiency (SCID), hypogammaglobulinemia, asplenia or functional asplenia).
Unstable medical or psychiatric illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to enrollment. Note: diabetes mellitus (Types 1 & 2) are not excluded if assessed by the principal investigator (PI) as well-controlled.
Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes:
Known contraindication to IM injection or blood draws (e.g. bleeding diathesis, acquired coagulopathy, significant bleeding or bruising) or to oral route of administration (unable to swallow tablets).
Any known allergies to components contained in the investigational product (including fish gelatin) or comparator or latex allergy (including polyethylene glycol [PEG] allergies) and/or history of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
Women who are pregnant (pregnancy tests will be performed at screening and prior to dosing), breastfeeding, or who plan to become pregnant during the study.
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:
a. Any history of: i. GI malignancy ii. malabsorption iii. pancreatobiliary disorders iv. inflammatory bowel disease v. irritable bowel disease vi. hiatal hernia vii. surgical resection b. History of diagnosis or treatment in past 5 years of: i. esophageal or gastric motility disorder ii. gastroesophageal reflux disorder iii. peptic ulcer iv. cholecystectomy.
Use of antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use during the study.
Use of drugs known to affect gastrointestinal motility including glucagon-like peptide 1 (GLP-1) receptor agonists including tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) within 30 days prior to drug administration.
Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the study.
Personal or familial history of hypercoagulable states to include personal past history of deep vein thrombosis (DVT).
Personal history of myocarditis or pericarditis.
Positive Hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at the screening visit.
History of drug, alcohol, or chemical abuse within 1 year of screening.
Positive urine drug screen for drugs of abuse at screening (except for previous marijuana use); concurrent or planned use of marijuana during the active study period are excluded. Positive urine drug screen (UDS) at screening due to prescribed stimulants will be reviewed on a case by case basis.
Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).
History of any form of angioedema.
History of GI bleeding including hematochezia (blood in stool) or melena (black stool) of unknown etiology or that has not been evaluated.
Any history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia, including:
i. Recent surgery other than fully healed cesarean delivery or excision/ biopsy of cutaneous lesions ii. Immobility (confined to bed or wheelchair for 3 or more successive days) iii. Head trauma with loss of consciousness or documented brain injury iv. Receipt of anticoagulants for prophylaxis of thrombosis v. Recent clinically significant infection including hospitalization for COVID-19 related illness.
Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
Study team member or first-degree relative of any study team member (inclusive of sponsor and site personnel involved in the study).
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 2 patient groups
Loading...
Central trial contact
Melanie Drayton; Christian Hummel
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal